PATIENT ALERT: Information regarding COVID-19. 

Clinical Research & Trials

USO 20417

A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer (D933LC00001)


Disease Types: Breast Cancer Research

Eligibility Requirements:

-advanced unresectable or metastatic triple negative breast cancer with measurable disease
-no prior treatment for metastatic breast cancer, prior treatment with immunotherapy including treatment on clinical trial with durvalumab
-No: allogenic organ transplant; history of or active autoimmune or inflammatory disorder(s); active infection including tuberculosis, HIV, Hep B, or Hep C; leptomeningeal carcinomatous; history of active primary immunodeficiency; untreated or uncontrolled brain metastasis; clinically significant cardiac arrythmias; coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure ≥ grade 2, or stroke within the last 6 months.

Available at: